Growth Metrics

Trinity Biotech (TRIB) Accumulated Depreciation & Amortization (2023)

Trinity Biotech recorded quarterly Accumulated Depreciation & Amortization of $35.0 million in Q4 2023.

Trinity Biotech's Accumulated Depreciation & Amortization history runs 1 years deep, the most recent figure standing at $35.0 million for Q4 2023.

  • In Q4 2023, Accumulated Depreciation & Amortization changed N/A year-over-year to $35.0 million; the TTM figure through Dec 2023 stood at $35.0 million (changed N/A YoY), while the FY2023 annual figure was $35.0 million, changed N/A from the prior year.
  • Accumulated Depreciation & Amortization came in at $35.0 million for Q4 2023 at Trinity Biotech.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $35.0 million in Q4 2023 to a low of $35.0 million in Q4 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Trinity Biotech 28,000.00 -5.11 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2023 35.03 Mn
Dec 31, 2023 35.03 Mn